Loading your page…
Each register with its number of medicines and a few of them.
Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.
Health Canada · 7 medicines
EMA · 1 medicine · Historical list
CBG-MEB · 1 medicine
PHARMAC · 1 medicine
SFDA · 1 medicine · Historical list
HSA · 1 medicine
TFDA · 1 medicine · Historical list
Every register, a page at a time. Strengths and packs are on each medicine’s page.
21 results
| Medicine | Register | Strength | Form | Status | Holder |
|---|---|---|---|---|---|
| Amphadase | United States | 150 UNITS/ML | injectable | Marketed | Amphastar Pharm |
| Vyvgart HytruloCombination | United States | 1008MG | injectable | Marketed | Argenx BV |
| Herceptin HylectaCombination | United States | 600MG | injectable | Marketed | Genentech INC |
| Tecentriq HybrezaCombination | United States | 125MG | injectable | Marketed | Genentech INC |
| Hydase | United States | 150 UNITS/ML | injectable | Not marketed | Akorn INC |
| Darzalex FasproCombination | United States | 120MG | injectable | Marketed | Janssen Biotech |
| Ocrevus ZunovoCombination | United States | 40MG | injectable | Marketed | Genentech INC |
| PhesgoCombination | United States | 1,200MG, 600MG | injectable | Marketed | Genentech INC |
| Rybrevant FasproCombination | United States | 10ML, 14ML | injection | Marketed | Janssen Biotech |
| Rybrevant FasproCombination | United States | 1,600MG/20,000 UNITS PER 10ML, 2,240MG/28,000 UNITS PER 14ML, 2,400MG/30,000 UNITS PER 15ML … | vial | Marketed | Janssen Biotech |
| Vitrase | United States | 200 UNITS/VIAL, 6,200 UNITS/VIAL | injectable | Marketed | Bausch and Lomb |
| Vyvgart HytruloCombination | United States | 1,000MG/5ML;10,000UNITS/5ML | Injection | Marketed | Argenx BV |
| Opdivo QvantigCombination | United States | 300MG/2.5ML;5,000UNITS/2.5ML | Injection | Marketed | Bristol-Myers Squibb Company |
| MetabatoneCombination | United States | Status unknown | |||
| Pest and Dustmite FormulaCombination | United States | Status unknown | |||
| Rituxan HycelaCombination | United States | 1400MG and 23400UNITS/11.7ML, 1600MG and 26800UNITS/13.4ML | solution | Marketed | Genentech INC |
| Opdivo QvantigCombination | United States | 600MG; 10000UNITS PER5ML | injectable | Marketed | Bristol-Myers Squibb |
| Opdivo QvantigCombination | United States | 600MG; 10000 UNITS PER 5ML | injectable | Marketed | Bristol-Myers Squibb |
| Hylenex Recombinant | United States | 150 UNITS/ML | injectable | Marketed | Halozyme Therap |
| Hyqvia | United States | 0.1 | Injection | Marketed | Takeda Pharmaceuticals U.S.A., Inc. |
| Guna-MatrixCombination | United States | Status unknown |
The same brand on several registers.
The companies holding its medicines, the most first.
Substances it shares a medicine with.
How the registers write it, in their own languages.
Compiled by Prognia from the public medicine registers of Anvisa, CBG-MEB, EMA, FDA, Health Canada, HSA, PHARMAC, SFDA and TFDA. Each medicine’s page names its own source, licence and attribution.
Report an error or request removalCorrections from a register or a company are welcome.
For reference and learning, not treatment advice. Always check the official product information.
